FindTrial
Sign In

Understanding the Immune Response in People with Migraine

Assessment of antinuclear antibody prevalence in migraine patients using indirect immunofluorescence assay method - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/096871
Enrollment
89
Registered
2025-11-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Control Intervention1: Nil: Nil

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Migraine with aura (MWA) and Migraine without aura (MWOA) patients 2.Patients above 18 years old 3.Confirmation of migraine by a neurologist

Exclusion criteria

Exclusion criteria: 1.Patients with additional comorbidity conditions were not allowed to participate. 2.Patients who have recently taken any immunosuppressants 3.Pregnant women were excluded 4.Patients with previous head injury

Design outcomes

Primary

MeasureTime frame
The outcome of this study will provide prevalence of exact ANA pattern in migraine patients.Timepoint: Blood will be collected at a single time point when patients experience a migraine pain (during the ictal phase).—

Secondary

MeasureTime frame
Role of ANA in migraine pain progressionTimepoint: Blood will be collected at a single time point when patients experience a migraine pain (during the ictal phase).—

Countries

India

Contacts

Public ContactAmeena Bee M

Sri Ramachandra Institute of Higher Education and Research

murugesan.a@sriramachandra.edu.in8870151588

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026